POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS

被引：1
|
作者：
Dorner, T. [1 ]
Tanaka, Y. [2 ]
Mosca, M. [3 ]
Bruce, I. N. [4 ]
Cardiel, M. [5 ]
Morand, E. F. [6 ]
Petri, M. A. [7 ]
Silk, M. [8 ]
Dickson, C. [8 ]
Meszaros, G. [8 ]
Issa, M. [8 ]
Zhang, L. [8 ]
Wallace, D. J. [9 ]
机构：
[1] Charite, Med Rheumatol & Clin Immunol, Berlin, Germany
[2] Univ Occupat & Environm Hlth, First Dept Internal Med, Kitakyushu, Fukuoka, Japan
[3] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[4] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England
[5] Centro Investigac Clin Morelia, Clinical Res, Morelia, Michoacan, Mexico
[6] Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic, Australia
[7] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD USA
[8] Eli Lilly & Co, Indianapolis, IN USA
[9] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Rheumatol Allergy & Immunol, Los Angeles, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0714
引用
收藏
页码：639 / 639
页数：1
相关论文
共 50 条
  • [21] Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
    Tam, LS
    Li, EK
    Wong, CK
    Lam, CWK
    Szeto, CC
    LUPUS, 2004, 13 (08) : 601 - 604
  • [22] Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials
    Dao Thai-Cuarto
    Christopher F. O’Brien
    Roland Jimenez
    Grace S. Liang
    Joshua Burke
    Drug Safety, 2018, 41 : 429 - 440
  • [23] Bromocriptine in systemic lupus erythematosus: A double-blind, randomized placebo-controlled study.
    AlvarezNemegyei, J
    CovarrubiasCobos, A
    EscalanteTriay, F
    SosaMunoz, G
    Jara, LJ
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1351 - 1351
  • [24] Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials
    Dao Thai-Cuarto
    O'Brien, Christopher F.
    Jimenez, Roland
    Liang, Grace S.
    Burke, Joshua
    DRUG SAFETY, 2018, 41 (04) : 429 - 440
  • [25] Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus Results of a phase I, placebo-controlled, double-blind, dose-escalation study
    McBride, Jacqueline M.
    Jiang, Jenny
    Abbas, Alexander R.
    Morimoto, Alyssa
    Li, Jing
    Maciuca, Romeo
    Townsend, Michael
    Wallace, Daniel J.
    Kennedy, William P.
    Drappa, Jorn
    ARTHRITIS AND RHEUMATISM, 2012, 64 (11): : 3666 - 3676
  • [26] LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study
    Alarcón-Segovia, D
    Tumlin, JA
    Furie, RA
    McKay, JD
    Cardiel, MH
    Strand, V
    Bagin, RG
    Linnik, MD
    Hepburn, B
    ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 442 - 454
  • [27] Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
    Grabar, Sophie
    Groh, Matthieu
    Bahuaud, Mathilde
    Costedoat-Chalumeau, Nathalie
    Le Guern, Veronique
    Fior, Renato
    Bienvenu, Boris
    Hachulla, Eric
    Hamidou, Mohamed
    Sibilia, Jean
    Mathian, Alexis
    Hanslik, Thomas
    Guillevin, Loic
    Batteux, Frederic
    Launay, Odile
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [28] Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study
    Grabar, Sophie
    Groh, Matthieu
    Bahuaud, Mathilde
    Le Guern, Veronique
    Costedoat-Chalumeau, Nathalie
    Mathian, Alexis
    Hanslik, Thomas
    Guillevin, Loic
    Batteux, Frederic
    Launay, Odile
    VACCINE, 2017, 35 (37) : 4877 - 4885
  • [29] Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials
    Regev, Arie
    Camporeale, Angelo
    Skljarevski, Vladimir
    Wang, Shufang
    Carter, Jeff
    NEUROLOGY, 2017, 88
  • [30] Hepatic Safety of Galcanezumab in Patients with Migraine: Results of Three Phase 2 Double-blind Placebo-controlled Trials
    Regev, A.
    Camporeale, A.
    Skljarevski, V
    Wang, S.
    Carter, J.
    HEADACHE, 2017, 57 : 182 - 182
12345